HC Wainwright Reaffirms Buy Rating for Verona Pharma (NASDAQ:VRNA)

HC Wainwright reaffirmed their buy rating on shares of Verona Pharma (NASDAQ:VRNA) in a research note published on Tuesday morning, Benzinga reports. The brokerage currently has a $36.00 target price on the stock. HC Wainwright also issued estimates for Verona Pharma’s FY2025 earnings at ($1.20) EPS.

Other equities research analysts also recently issued reports about the company. Canaccord Genuity Group increased their price target on Verona Pharma from $35.00 to $37.00 and gave the stock a buy rating in a report on Monday, July 22nd. Truist Financial increased their price target on Verona Pharma from $32.00 to $38.00 and gave the stock a buy rating in a report on Friday, June 28th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Verona Pharma currently has an average rating of Buy and a consensus price target of $36.00.

Verona Pharma Stock Performance

NASDAQ VRNA opened at $29.99 on Tuesday. The business has a 50-day moving average price of $25.46 and a 200-day moving average price of $18.74. Verona Pharma has a twelve month low of $11.39 and a twelve month high of $30.73. The firm has a market cap of $2.44 billion, a price-to-earnings ratio of -38.95 and a beta of 0.44. The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.72.

Verona Pharma (NASDAQ:VRNA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53). During the same quarter last year, the firm posted ($0.11) earnings per share. As a group, equities research analysts predict that Verona Pharma will post -2.07 EPS for the current fiscal year.

Institutional Trading of Verona Pharma

Institutional investors have recently made changes to their positions in the business. Jennison Associates LLC raised its stake in Verona Pharma by 0.5% in the 1st quarter. Jennison Associates LLC now owns 1,593,833 shares of the company’s stock worth $25,645,000 after acquiring an additional 8,448 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in Verona Pharma by 71.4% in the 1st quarter. Hennion & Walsh Asset Management Inc. now owns 67,365 shares of the company’s stock worth $1,084,000 after buying an additional 28,071 shares during the last quarter. Parkman Healthcare Partners LLC boosted its holdings in Verona Pharma by 20.8% in the 4th quarter. Parkman Healthcare Partners LLC now owns 504,742 shares of the company’s stock worth $10,034,000 after buying an additional 86,809 shares during the last quarter. Sei Investments Co. boosted its holdings in Verona Pharma by 3.7% in the 1st quarter. Sei Investments Co. now owns 74,294 shares of the company’s stock worth $1,195,000 after buying an additional 2,640 shares during the last quarter. Finally, Affinity Asset Advisors LLC boosted its holdings in Verona Pharma by 53.1% in the 4th quarter. Affinity Asset Advisors LLC now owns 563,824 shares of the company’s stock worth $11,209,000 after buying an additional 195,495 shares during the last quarter. Institutional investors and hedge funds own 85.88% of the company’s stock.

Verona Pharma Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.